Effect on Body Weight and Safety of RC-1291, a Novel, Orally Available Ghrelin Mimetic and Growth Hormone Secretagogue: Results of a Phase I, Randomized, Placebo-Controlled, Multiple-Dose Study in Healthy Volunteers
Open accessThe DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index.
Abstract
Purpose.: RC-1291 is a novel, oral ghrelin mimetic and growth hormone (GH) secretagogue being developed to increase appetite and lean muscle mass in patients with cancer-associated anorexia/cachexia. This randomized, double-blind, placebo-controlled, multiple-dose, dose-escalation phase I study in healthy volunteers evaluated RC-1291 once daily (qd) and twice daily (bid) for effect on body weight and safety. Methods.: The study was conducted with three sequential groups of volunteers. Panel A subjects (n = 8) received placebo or RC-1291, 25 mg qd, for 5 days. Panel B subjects received RC-1291, 25 mg bid or 50 mg qd, for 6 days then crossed over to the other dosage for 5 days (n = 12); three subjects received placebo for all 11 doses to maintain double-blinding. Panel C subjects (n = 9) received placebo or RC-1291, 75 mg qd, for 6 days. Results.: Subjects who received RC-1291, 50 or 75 mg, had significant dose-related weight gain after 6 days versus placebo, with the greatest increases seen with daily dosing. The mean increase in weight from baseline after 50 mg qd was 1.25 ± 0.725 kg (p = .0022 versus placebo), and after 75 mg qd it was 1.16 ± 0.651 kg (p = .0022 versus placebo). One subject in the 50 mg qd group had moderate transient elevation in aspartate aminotransferase and alanine aminotransferase levels. No other laboratory or clinical adverse events of consequence were reported. Conclusions.: Results indicate that RC-1291 produces dose-related increases in body weight with no dose-limiting adverse effects, and may be an effective treatment for anorexia/cachexia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Anamorelin is safe, well tolerated and stimulates appetite by promoting expression of GH, IGF1 and IGF-binding protein 3 (REFS435,436), which reverses muscle atrophy in mice437.”
From Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies (2018) · cites this paper as [436]
Citations
Cites
Ghrelin is a growth-hormone-releasing acylated peptide from stomach
Kojima, M., Hosoda, H., Date, Y., Nakazato, M., Matsuo, H., & Kangawa, K. (1999) · Nature · doi:10.1038/45230 · Cited by 8,479 · cited 2×
“Since the discovery of ghrelin in 1999 [ 14 ], its orexigenic properties have been investigated in preclinical [16– 25] and clinical [30–32, 33] trials.”
BackgroundGhrelin induces adiposity in rodents
Tschöp, M., Smiley, D. L., & Heiman, M. L. (2000) · Nature · doi:10.1038/35038090 · Cited by 3,949
A role for ghrelin in the central regulation of feeding
Nakazato, M., Murakami, N., Date, Y., Kojima, M., Matsuo, H., Kangawa, K., & Matsukura, S. (2001) · Nature · doi:10.1038/35051587 · Cited by 3,443
Ghrelin enhances appetite and increases food intake in humans
Wren, A. M., Seal, L. J., Cohen, M. A., Brynes, A. E., Frost, G. S., Murphy, K. G., Dhillo, W. S., Ghatei, M. A., & Bloom, S. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.12.8111 · Cited by 2,494
Prognostic effect of weight loss prior tochemotherapy in cancer patients
Dewys, W. D., Begg, C., Lavin, P. T., Band, P. R., Bennett, J. M., Bertino, J. R., Cohen, M. H., Douglass, H. O., Engstrom, P. F., Ezdinli, E. Z., et al. (1980) · The American Journal of Medicine · doi:10.1016/s0149-2918(05)80001-3 · Cited by 2,354
The Novel Hypothalamic Peptide Ghrelin Stimulates Food Intake and Growth Hormone Secretion
Wren, A. M., Small, C. J., Ward, H. L., Murphy, K. G., Dakin, C. L., Taheri, S., Kennedy, A. R., Roberts, G. H., Morgan, D. G. A., Ghatei, M. A., et al. (2000) · Endocrinology · doi:10.1210/endo.141.11.7873 · Cited by 1,593
Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin
Asakawa, A., Inui, A., Kaga, O., Yuzuriha, H., Nagata, T., Ueno, N., Makino, S., Fujimiya, M., Niijima, A., Fujino, M. A., et al. (2001) · Gastroenterology · doi:10.1053/gast.2001.22158 · Cited by 1,177
Tisdale, M. J. (2002) · Nature Reviews Cancer · doi:10.1038/nrc927 · Cited by 982
Shintani, M., Ogawa, Y., Ebihara, K., Aizawa-Abe, M., Miyanaga, F., Takaya, K., Hayashi, T., Inoue, G., Hosoda, K., Kojima, M., et al. (2001) · Diabetes · doi:10.2337/diabetes.50.2.227 · Cited by 847
Sun, Y., Wang, P., Zheng, H., & Smith, R. G. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0305930101 · Cited by 745
Research works printed but not linked: 1
- Kumor, 2006, Biologic activity of RC-1291, a novel oral ghrelin mimetic for the treatment of cancer anorexia/cachexia: Results from a phase I randomized, double-blind, placebo-controlled clinical trial in healthy volunteers, Support Care Cancer, 14, 593
Cited by
Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies
Batsis, J. A., & Villareal, D. T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0062-9 · Cited by 1,382
Ghrelin in the regulation of body weight and metabolism
Castañeda, T. R., Tong, J., Datta, R., Culler, M., & Tschöp, M. H. (2010) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2009.10.008 · Cited by 352
Katakami, N., Uchino, J., Yokoyama, T., Naito, T., Kondo, M., Yamada, K., Kitajima, H., Yoshimori, K., Sato, K., Saito, H., et al. (2018) · Cancer · doi:10.1002/cncr.31128 · Cited by 239
Ghrelin Gene Products and the Regulation of Food Intake and Gut Motility
Chen, C.-Y., Asakawa, A., Fujimiya, M., Lee, S.-D., & Inui, A. (2009) · Pharmacological Reviews · doi:10.1124/pr.109.001958 · Cited by 239
Garcia, J. M., Boccia, R. V., Graham, C. D., Yan, Y., Duus, E. M., Allen, S., & Friend, J. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71154-4 · Cited by 218
Self-citation
Metadata
- Authors
- Garcia, J. M., & Polvino, W. J.
- Affiliations
- a Division of Diabetes, Endocrinology and Metabolism, Michael E. DeBakey Veterans Affairs Medical Center and Baylor College of Medicine, Houston, Texas, USA
- b Sapphire Therapeutics, Inc., Bridgewater, New Jersey, USA
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-05-01
- Volume
- 12
- Issue
- 5
- Pages
- 594-600
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2166836966
- Cited by
- 129
- References
- 33
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 4 · 2023: 4 · 2022: 4 · 2021: 3 · 2020: 4 · 2019: 7 · 2018: 4 · 2017: 9 · 2016: 4 · 2015: 8 · 2014: 10 · 2013: 9 · 2012: 14
- FWCI
- 3.67
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- The Oncologist (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Food and Drug Administration
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Keywords
- growth hormone secretagogues, weight gain, dose-dependent effects, drug safety, cachexia, appetite, lean muscle mass, healthy volunteers, dose escalation
- MeSH terms
- Administration, Oral, Adult, Alanine Transaminase, Analysis of Variance, Aspartate Aminotransferases, Blood Pressure, Body Weight, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Reference Values, Time Factors, Biomarkers, Treatment Outcome, Ghrelin, Receptors, Ghrelin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect on Body Weight and Safety of RC-1291, a Novel, Orally Available Ghrelin Mimetic and Growth Hormone Secretagogue: Results of a Phase I, Randomized, Placebo-Controlled, Multiple-Dose Study in Healthy Volunteers. https://app.cochat.ai/papers/10.1634/theoncologist.12-5-594
- The paper
- Garcia, J. M., & Polvino, W. J. (2007). Effect on Body Weight and Safety of RC-1291, a Novel, Orally Available Ghrelin Mimetic and Growth Hormone Secretagogue: Results of a Phase I, Randomized, Placebo-Controlled, Multiple-Dose Study in Healthy Volunteers. The Oncologist. https://doi.org/10.1634/theoncologist.12-5-594
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.